Reports Q4 revenue $164.7M, consensus $289.25M. Cash, cash equivalents, and marketable securities were $1.94B on December 31, 2025, vs. $1.14B on December 31, 2024.”We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience,” said CEO Matthew Klein. “With our robust commercial engine, innovative R&D programs, and strong financial position, we look forward to continued success as we approach cash flow breakeven.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Closing Bell Movers: DraftKings down 15% after earnings miss
- PTC Therapeutics Withdraws Translarna NDA After FDA Feedback
- PTC Therapeutics price target raised to $97 from $96 at BofA
- PTC Therapeutics price target raised to $75 from $63 at TD Cowen